Underscores the Company's ambition to harness the power of ultrasound in
precision therapeutics amplification
OSLO/LONDON: 6 DECEMBER, 2021: Exact Therapeutics AS ("EXACT-Tx", or "the
Company" Euronext Growth: EXTX), a clinical-stage precision health company
evaluating Acoustic Cluster Therapy (ACT®) across multiple therapeutic areas,
today is delighted to announce the appointment of Anders Wold to its Board of
Anders Wold has nearly forty years of leadership experience in the healthcare
and ultrasound industry. Anders is currently Business Development and Strategic
Advisor to the GE Healthcare President and CEO. He was, until Spring 2021, the
President and CEO of GE Healthcare Clinical Care Solutions, a US$5 billion
business with more than 5,000 employees worldwide. Clinical Care Solutions
provides clinicians and frontline caregivers with a variety of medical solutions
including ultrasound, monitoring technology, maternal-infant care, anesthesia
and respiratory care, and cardiology.
Anders joined GE in 1998 through the acquisition of Diasonics/Vingmed
Ultrasound, a Norway-based technology start-up. Anders has held industry
leadership roles in North America, Asia and Europe. He grew the GE Healthcare
Cardiovascular Ultrasound business from US$50 million to US$500 million in sales
by 2008. He led the Global Ultrasound business from 2009 to July 2016, growing
it into the global industry leader with more than US$2.5 billion in revenue
annually, and creating new markets through technical leadership, product cost
productivity and customer focus. In July 2016, Anders was named President and
CEO of the new Clinical Care Solutions business. In his nearly forty years in
the ultrasound industry Anders has been involved in launching 23 new products
including the handheld Ultrasound Vscan AirTM.
Anders graduated from the Norwegian Military Academy in 1978 and completed his
BSc in Biomedical Electronics from the University of Salford, UK, in 1983. He
was President-elect for ANSA - Norwegian Student Abroad and completed his
business studies at BI, Oslo School of Economics in 1988. He has a cross country
ski coach degree and was National Team Coach for Norway in 1982.
Dr Masha Strømme, Executive Chair of the Board, stated: "We are delighted to
welcome Anders Wold to our Board. Anders has, in his capacity as a Senior
Executive at GE Healthcare for several decades, been a champion of ultrasound
innovation and precision health. The Company will benefit tremendously from his
extensive experience as we look to expand the clinical trials and development of
the ACT® technology platform in 2022 and the years ahead."
Anders Wold, Director of the Board, stated: "I am excited to be joining the
EXACT Therapeutics Board. The Company has developed a unique method in the
crossover between Bio Pharma and Med Tech. Applying ultrasound to improve the
efficacy of pharma in cancer treatment is novel, exciting, and the ongoing
clinical development of ACT® is very promising for patient outcomes. I look
forward to working with the EXACT team to accelerate the ultrasound application
and build out the ACT® platform. These are exciting times and ACT® may well be
Precision Health at the next level."
For more information, please contact:
Optimum Strategic Communications
Mary Clark/ Manel Mateus/ Vici Rabbets
Tel: +44 (0) 208 078 0457
EXACT-Tx is a clinical stage Norwegian biotech company developing a technology
platform for targeted therapeutic enhancement - Acoustic Cluster Therapy (ACT®).
ACT® follows a unique approach to ultrasound-mediated, targeted drug
enhancement - with the potential to significantly amplify the clinical utility
of a wide range of therapeutic agents across a multitude of indications
including within oncology (chemotherapy, immunotherapy), infectious diseases,
and brain diseases. www.exact-tx.com
oACT® is a proprietary formulation consisting of microbubbles and microdroplets
that are activated through the application of ultrasound with the consequent
increase in targeted delivery of a co-administered therapeutic agent.
oACT® is supported by a strong and broad preclinical package demonstrating
therapeutic enhancement in multiple oncology models (pancreatic, breast, colon,
prostate) as well as blood-brain barrier penetration.
oInitial focus of the Company is in oncology, however the ACT® platform has
potential across therapeutic areas (infectious diseases, CNS, immunotherapy) and
Forward looking statements
This announcement and any materials distributed in connection with this
announcement may contain certain forward-looking statements. By their nature,
forward-looking statements involve risk and uncertainty because they reflect the
Company's current expectations and assumptions as to future events and
circumstances that may not prove accurate. A number of material factors could
cause actual results and developments to differ materially from those expressed
or implied by this forward-looking statement.
Click here for more information
© Oslo Bors ASA, source Oslo Stock Exchange